Episodes 121-135 of 604
Real-World Data on Treatment Choices for mccRCC
Project Oncology®Real-World Data on Treatment Choices for mccRCC
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Project Oncology®Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and HematologySunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and HematologyTAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyUpdates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyTAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and HematologyPhase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and HematologyUpdates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and HematologyReal-World Sequencing and Survival in Locally Advanced Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and HematologyEvolving Trends in Germline Genetic Testing for Prostate Cancer
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
